Taken together, we showed that CBP expression might be a valuable prognostic marker and the specific blockade of its interaction with Beta-Catenin a potential therapy option for low-risk patients with HPV-positive HNSCC. Here, CREBBP is linked to head and neck squamous cell carcinoma.